GILEAD SCIENCES, INC.
SEC CIK 882095 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| ASMB | ASSEMBLY BIOSCIENCES, INC. | 10% | 4.51M | $20.10M | — | 3 | 2024-06-17 | 2025-08-08 |
| RCUS | Arcus Biosciences, Inc. | 10% | 31.42M | $354.45M | — | 3 | 2023-06-28 | 2025-02-18 |
| XLO | Xilio Therapeutics, Inc. | 10% | 9.11M | $2.20M | — | 2 | 2024-04-02 | 2024-12-18 |
| KYTX | Kyverna Therapeutics, Inc. | 10% | 3.22M | $20.02M | — | 2 | 2024-02-12 | 2024-02-12 |
| KLRS | Kalaris Therapeutics, Inc. | 10% | 16.64M | $10.99M | — | 1 | 2023-06-27 | 2023-06-27 |
Most active insiders at ASMB, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Bjorkquist Jeanette M | PFO, PAO | — | $9,429 |
| 2 | White Nicole S | Chief Manufacturing Off | — | $5,258 |
| 3 | Gaggar Anuj | Chief Medical Off | — | — |
| 4 | Delaney William E IV | CSO | — | — |
| 5 | Okazaki Jason A | CEO, Pres, Dir | — | — |
GILEAD SCIENCES, INC. made no open-market trades at ASMB in the last 12 months.
Transactions 11
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-03 | 2025-08-08 | ASMB | ASSEMBLY BIOSCIENCES, INC. | GILEAD SCIENCES, INC. | 10% | P - Purchase | — | +2.30M | 4.51M | +104% | — |
| 2025-02-20 | 2025-02-18 | RCUS | Arcus Biosciences, Inc. | GILEAD SCIENCES, INC. | 10% | P - Purchase | $11.00 | +1.36M | 31.42M | +5% | +$15.00M | |
| 2024-12-23 | 2024-12-19 | ASMB | ASSEMBLY BIOSCIENCES, INC. | GILEAD SCIENCES, INC. | 10% | P - Purchase | $21.37 | +940.5K | 2.21M | +74% | +$20.10M | |
| D | 2024-12-19 | 2024-12-18 | XLO | Xilio Therapeutics, Inc. | GILEAD SCIENCES, INC. | 10% | P - Purchase | $1.04 | +1.76M | 9.11M | +24% | +$1.83M |
| D | 2024-06-20 | 2024-06-17 | ASMB | ASSEMBLY BIOSCIENCES, INC. | GILEAD SCIENCES, INC. | 10% | P - Purchase | — | +179.5K | 1.27M | +16% | — |
| D | 2024-04-03 | 2024-04-02 | XLO | Xilio Therapeutics, Inc. | GILEAD SCIENCES, INC. | 10% | P - Purchase | $0.76 | +485.2K | 7.35M | +7% | +$368.8K |
| D | 2024-02-13 | 2024-02-12 | KYTX | Kyverna Therapeutics, Inc. | GILEAD SCIENCES, INC. | 10% | C - Cnv Deriv | — | +3.22M | 3.22M | New | — |
| D | 2024-02-13 | 2024-02-12 | KYTX | Kyverna Therapeutics, Inc. | GILEAD SCIENCES, INC. | 10% | P - Purchase | $22.00 | +910.0K | 4.13M | +28% | +$20.02M |
| 2024-01-31 | 2024-01-29 | RCUS | Arcus Biosciences, Inc. | GILEAD SCIENCES, INC. | 10% | P - Purchase | $21.00 | +15.24M | 30.06M | +103% | +$320.00M | |
| 2023-06-30 | 2023-06-28 | RCUS | Arcus Biosciences, Inc. | GILEAD SCIENCES, INC. | 10% | P - Purchase | $19.26 | +1.01M | 14.82M | +7% | +$19.45M | |
| 2023-06-28 | 2023-06-27 | KLRS | Kalaris Therapeutics, Inc. | GILEAD SCIENCES, INC. | 10% | P - Purchase | $3.75 | +2.93M | 16.64M | +21% | +$10.99M |
Purchase Sale Sale after option exercise All abbreviations